eGenesis raises $38m for CRISPR-powered xenotransplantation

Share

eGenesis raises $38m for CRISPR-powered xenotransplantationA Cambridge, MA.-based firm got a $38 million boost towards it goal of harvesting animal organs to give to humans in dire need of a transplant. eGenesis, a spin-out from Harvard University, hopes to improve the supply of organs for patients that are stuck on the transplant waiting list.

While the seemingly science-fiction field of xenotransplantation is far away from bringing products into the clinic, it has grown in recent years thanks to the development of biological modification techniques like CRISPR-Cas9.

Get the full story at our sister site, MassDevice.

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

Join us in Southern California this December for DeviceTalks West on 12/11-12/12

textadimage We've attracted a diverse group of thought leaders from some of the Golden State's best medtech companies — including Bigfoot Biomedical, BD, Alphabet's Verily, Integer, Medtronic Neurovascular, Medtronic Diabetes, Smith & Nephew and many more for DeviceTalks West.

Check out our web site for latest news on speakers, agenda and event information.


Get your tickets today! »

Speak Your Mind

*